Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

Blood Cancer Breakthroughs: New Therapies for Patients

Faron is a partner of Blood Cancer United’s (formerly Leukemia & Lymphoma Society) Therapy Acceleration Program (TAP).
The collaboration began in June 2022, when LLS TAP participated in Faron’s €5 million funding round for the development of Bex. A second investment apparently in 2023.

Bono can be heard on Jan 30, 2026, at 12 noon EST / 9 am PST. That would be 7:00 PM in Finland. There is a registration link. You are expected to provide information about yourself and how you are related to the matter.

12 Likes